COPENHAGEN: Denmark’s Novo Nordisk on Monday stated it has agreed to purchase Cardior Prescription drugs for as much as 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline. The acquisition is according to the Danish drugmaker’s goal to increase its concentrate on diabetes and weight-loss therapies to incorporate heart problems remedies. “By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programmes across all phases of clinical development,” Novo stated in an announcement. The deal contains Cardior’s lead compound CDR132L, at the moment in section 2 scientific improvement for the therapy of coronary heart failure, Novo stated. The transaction value contains an upfront fee and extra funds if sure improvement and industrial milestones are achieved, the corporate stated, including it will fund the acquisition from monetary reserves.
#Novo #Nordisk #purchase #Cardior #Prescription drugs #billion
Novo Nordisk to purchase Cardior Prescription drugs for as much as $1.1 billion
You Might Also Like
Purchase or promote: Wockhardt to MOIL, Vaishali Parekh recommends three shares to purchase right now — April 10
How Apple Watch helped a Bangalore-based techie escape a poisonous office and enhance his cardio well being |
Bitcoin surges to document above $69,000 on sustained ETF demand
How AI helped Nvidia to grow to be a $2 trillion firm |
Gold fee crosses new milestone of Rs 70,000 per 10 gm
